Hansa Biopharma announces increase in number of shares and votes
LUND, Sweden, July 31, 2020 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announces that the Company' s registered share capital and number of outstanding shares and votes have increased during the month of July.
As previously communicated, the board of directors of Hansa Biopharma resolved on a share issue of 4,447,345 ordinary shares, on July 8, 2020, by virtue of authorization by the Annual General Meeting held on June 23, 2020.
As of July 31, 2020, the total number of registered and outstanding shares of Hansa Biopharma amounts to 45,894,909, of which 44,473,452 are ordinary shares and 1,421,457 are class C shares. As of today, the number of votes in Hansa Biopharma amounts to 44,615,597.7 and the registered share capital amounts to SEK 45,894,909.
For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Mobile: +46 (0) 709-298 269
Head of Corporate Communications
Mobile: +46 (0) 768-198 326
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
SOURCE Hansa Biopharma AB
Upcoming Life Sciences Events
- August 2020
- ChinaBio® Partnering Forum 2020 Digital
- Biotechgate Digital Partnering Event
- September 2020
- Basel: Pharma-Biotech Product & Company Valuation
Latest company news
There are currently no news available for this portal